GLP-1 receptor agonists (semaglutide — brand names Ozempic and Wegovy — and others) are generating significant interest in the PCOS community.

What they do: These medications mimic a hormone called GLP-1, which: • Slows gastric emptying (you feel full longer) • Reduces appetite • Improves insulin secretion • Has direct effects on insulin resistance

Emerging evidence in PCOS:

• Several small trials show significant weight loss in PCOS (more than with metformin alone) • Improvements in insulin resistance • Reduction in androgen levels • Improved menstrual regularity • Some reports of restored ovulation

Important context:

• NOT specifically approved for PCOS — use is "off-label" • Cost is a major barrier — these medications are expensive and insurance coverage varies • Supply shortages have been a persistent problem • Common side effects: nausea (often severe initially), vomiting, diarrhea, constipation • Long-term safety data is still being collected • Must be stopped before pregnancy (discuss timeline with your doctor) • Effects reverse when the medication is stopped in most people

GLP-1 medications may represent a significant advance for PCOS with insulin resistance and weight challenges, but they're still early in PCOS-specific research. Discuss with your endocrinologist whether they're appropriate for your situation.